Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Holicek

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Trends in Cancer|September 1, 2023
Interferon signaling restrains renal cell carcinoma heterogeneityPeter Holicek, Jitka Fucikova, Lorenzo Galluzzi
Current Atherosclerosis Reports|May 7, 2026
Neuroimmune Dynamics in Diseases of the Arterial Wall: Mechanistic Foundations and Translational ProspectsQi Guo, Peter Holicek, Laura Tarnawski, et al.
Immunological Reviews|September 5, 2023
Type I interferon and cancerPeter Holicek, Emma Guilbaud, Vanessa Klapp, et al.
Methods in Enzymology|January 18, 2020
Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral bloodPeter Holicek, Iva Truxova, Lenka Kasikova, et al.
European Journal of Immunology|July 11, 2024
Immune response to cold exposure: Role of γδ T cells and TLR2-mediated inflammationDaniel Vasek, Peter Holicek, Frantisek Galatik, et al.
Trends in Cancer|February 19, 2022
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agentsJitka Fucikova, Lenka Palova-Jelinkova, Vanessa Klapp, et al.
Oncoimmunology|March 24, 2021
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patientsJana Rakova, Iva Truxova, Peter Holicek, et al.
Haematologica|October 5, 2019
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patientsIva Truxova, Lenka Kasikova, Cyril Salek, et al.
Cell Death & Disease|March 25, 2023
Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patientsPeter Holicek, Iva Truxova, Jana Rakova, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 4, 2026
Lymphocyte Antigen 6G Mediates Vagotomy-Associated Reduction in Body WeightTing Liu, April S Caravaca, Min Cai, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Trends in Cancer|September 1, 2023
Interferon signaling restrains renal cell carcinoma heterogeneityPeter Holicek, Jitka Fucikova, Lorenzo Galluzzi
Current Atherosclerosis Reports|May 7, 2026
Neuroimmune Dynamics in Diseases of the Arterial Wall: Mechanistic Foundations and Translational ProspectsQi Guo, Peter Holicek, Laura Tarnawski, et al.
Immunological Reviews|September 5, 2023
Type I interferon and cancerPeter Holicek, Emma Guilbaud, Vanessa Klapp, et al.
Methods in Enzymology|January 18, 2020
Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral bloodPeter Holicek, Iva Truxova, Lenka Kasikova, et al.
European Journal of Immunology|July 11, 2024
Immune response to cold exposure: Role of γδ T cells and TLR2-mediated inflammationDaniel Vasek, Peter Holicek, Frantisek Galatik, et al.
Trends in Cancer|February 19, 2022
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agentsJitka Fucikova, Lenka Palova-Jelinkova, Vanessa Klapp, et al.
Oncoimmunology|March 24, 2021
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patientsJana Rakova, Iva Truxova, Peter Holicek, et al.
Haematologica|October 5, 2019
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patientsIva Truxova, Lenka Kasikova, Cyril Salek, et al.
Cell Death & Disease|March 25, 2023
Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patientsPeter Holicek, Iva Truxova, Jana Rakova, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 4, 2026
Lymphocyte Antigen 6G Mediates Vagotomy-Associated Reduction in Body WeightTing Liu, April S Caravaca, Min Cai, et al.
Pageof 2